mRNA Vaccine for Melanoma

October 2026. A personalized mRNA vaccine for advanced melanoma moves toward FDA review.

Table of Contents:

  1. Heading Toward FDA Approval

  2. The Phase 3 Trial

  3. What the Results Showed

  4. Weighing the Benefits and Risks

The Overview

Approximately 15 years ago, people with advanced melanoma, the most deadly skin cancer, had a survival rate of a few months. Today, over half of the people treated are effectively cured with immunotherapies that boost the immune system, or targeted drugs that focus on specific genetic or protein abnormalities. This article discusses a new melanoma vaccine for people who have had surgery and did not respond to follow-up post-surgical immunotherapy alone.

Heading Toward FDA Approval

Two pharmaceutical companies, Merck and Moderna, are in discussions with the FDA for approval of their new mRNA vaccine for the treatment of melanoma. The companies reported their findings at the European Society for Medical Oncology, and the results have also been accepted in the prestigious US publication, the New England Journal of Medicine.

The Phase 3 Trial

This is a Phase 3 human melanoma trial of 1,137 patients, stage 2B to stage 4, who are considered to have more advanced disease and who had been surgically treated prior to entering the study. This was a randomized study, with one group receiving the monoclonal antibody cancer treatment Keytruda as standard therapy and the second group receiving the same standard therapy along with a personalized, tailored mRNA vaccine called Intismeran. This vaccine is made of synthetic mRNA that encodes an individual’s own unique genetic coding for up to 34 melanoma mutations.

What the Results Showed

The study assessed recurrence-free survival (RFS), or the time the patient has without return of disease, and distant metastasis-free survival (DMFS). After two years, the patients that received Intismeran and Keytruda had a 42% reduction in recurrence or death compared to the standard treatment with Keytruda or placebo. This meant that after two years, 82% were alive with no recurrence, cancer free, versus 70% on Keytruda alone.

For DMFS, the combination treatment reduced the risk of distant metastasis by 38% compared with the standard Keytruda treatment group. At the end of the trial, 88% of the combination treatment group of Intismeran and Keytruda were alive without distant metastasis, while 80% of the Keytruda-only group were alive without distant metastasis.

These effects were less robust when compared to a 5-year Phase 2 study, in which the Intismeran and Keytruda group showed a 49% reduction in recurrence or death and a 58% reduction in the risk of distant metastasis or death.

Weighing the Benefits and Risks

During the Covid pandemic, however, there were concerns surrounding the use of synthetically created mRNA for vaccines. The technology has faced questions about the safety of mRNA treatments, and current research has yet to resolve the issue. While conclusions concerning this technology are yet to be determined, in the setting of advanced melanoma when other therapies have proved unsuccessful, patients and their oncologists will need to weigh the benefit against the potential risk of mRNA vaccines.